Trial Profile
Open-Label Extension Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mogamulizumab (Primary)
- Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 29 Jun 2016 New trial record